Immunity, inflammation and disease.
Publisher:
John Wiley and Sons Ltd,
Country: England
Language: English
Start Year:2013 -
ISSN:
2050-4527 (Electronic)
2050-4527 (Linking)
2050-4527 (Linking)
Impact Factor
3.2
2023
| NLM ID: | 101635460 |
| (OCoLC): | 864027485 |
| LCCN: | 2013247786 |
Immunomodulatory asthma therapy in the equine animal model: A dose-response study and evaluation of a long-term effect. Equine asthma represents a naturally occurring animal model for human allergic neutrophilic asthma. Inhalative nanoparticle-bound cytosine-phosphate-guanosine (CpG-GNP) immunotherapy, independent of specific allergens, has already shown promising clinical and immunological results in previous studies and offers the possibility to treat the underlying cause of the disease. This study analyses the relationship between dose and response, and evaluates a possible long-term effect. In the prospective, randomised, double-blind clinical field study, 29 horses suffering from equine asthma received 10 ...
A comparison of nanoparticullate CpG immunotherapy with and without allergens in spontaneously equine asthma-affected horses, an animal model. New therapeutic strategies to modulate the immune response of human and equine allergic asthma are still under extensive investigation. Immunomodulating agents stimulating T-regulatory cells offer new treatment options beyond conventional symptomatic treatment or specific immunotherapy for human and equine allergic airway diseases, with the goal of a homoeostatic T-helper cell balance. The aim of this study was to evaluate the effects of a nebulized gelatin nanoparticle-CpG formulation (CpG-GNP) with and without specific allergens for the treatment of spontaneous allergic equine asthma as a mo...